Sertoli-cell-only syndrome (SCO)
Also known as: Sertoli-cell-only syndrome, Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Sertoli-cell-only syndrome (SCO) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Sertoli-cell-only syndrome (SCO) uses ICD-10 Q55.0 across Pediatrics specialty care.
- 3 Typical cash cost range: Primary evaluation for Sertoli-cell-only syndrome (SCO) incorporates growth-chart trajectory review [Sertoli-cell-only syndrome (SCO) Q55.0] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Sertoli-cell-only syndrome (SCO): maintaining Pediatric Hemoglobin & in Sertoli-cell-only syndrome (SCO) (Q55.0: Lead Screen) within Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q55.0).
Ask our AI Specialists anything about Sertoli-cell-only syndrome (SCO)
What Is Sertoli-cell-only syndrome (SCO)?
Recognized across U.S. clinical coding as Q55.0 (Pediatrics), Sertoli-cell-only syndrome (SCO) (also termed Sertoli-cell-only syndrome or Disorder) is evaluated via growth-chart trajectory review [Sertoli-cell-only syndrome (SCO) Q55.0] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Sertoli-cell-only syndrome (SCO) (code Q55.0) is early intervention timing [Sertoli-cell-only syndrome (SCO) Q55.0], which Children's & Adolescent Health clinicians address while surveilling Pediatric Hemoglobin & in Sertoli-cell-only syndrome (SCO) (Q55.0: Lead Screen) (Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q55.0)).
Common Symptoms & Clinical Signs
- • Presentation of Sertoli-cell-only syndrome (SCO) (Q55.0): growth velocity shifts, in Sertoli-cell-only syndrome (SCO) (Q55.0: newborn feeding/jaundice signs,)
- • Secondary Sertoli-cell-only syndrome (SCO) clinical sign: acute childhood fever, in Sertoli-cell-only syndrome (SCO) (Q55.0: barking cough, wheezing,)
- • Symptom flares in Sertoli-cell-only syndrome (SCO) correlating with Pediatric Hemoglobin & in Sertoli-cell-only syndrome (SCO) (Q55.0: Lead Screen) deviation outside Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q55.0)
- • Functional pediatrics impact requiring growth-chart trajectory review [Sertoli-cell-only syndrome (SCO) Q55.0] evaluation (Q55.0)
Sertoli-cell-only syndrome (SCO) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q55.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Sertoli-cell-only syndrome (SCO) (Q55.0: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q55.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Sertoli-cell-only syndrome (SCO) (Q55.0: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q55.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sertoli-cell-only syndrome (SCO)
Treatment selection for Sertoli-cell-only syndrome (SCO) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sertoli-cell-only syndrome (SCO))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| What the Latest Evidence Really Says About Vasodilators for persistent lung high blood pressure of the newborn: A network Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN. Pediatric pulmonology • 2024-12-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39193897 ↗ |
| Can This Approach Help? Inside the Latest Research on Dupilumab Efficacy in Children with eczema with Different Phenotypes and Treatment with dupilumab improved signs, symptoms, and quality of life, and reduced AD-related serum biomarkers in young children with moderate-to-severe AD with different phenotypes and endotypes. Advances in therapy • 2025-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40338484 ↗ |
Sertoli-cell-only syndrome (SCO) Patient Community & “People Like Me” Threads
Filter Sertoli-cell-only syndrome (SCO) community threads and patient logs by age, biological sex, dosage, and treatment duration.